신경보철 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 유형별, 기술별, 용도별, 지역별, 부문별 예측(2025-2033년)

Neuroprosthetics Market Summary

The global neuroprosthetics market size was estimated at USD 14.62 billion in 2024 and is projected to reach USD 47.0 billion by 2033, growing at a CAGR of 13.69% from 2025 to 2033. The market is driven by the increasing prevalence of neurological, cardiac, and kidney disorders, as well as ongoing advancements in medical technology.

In addition, expanded research efforts and a greater focus on industry growth are anticipated to support the market in the coming years. The burden of neurological disorders such as Parkinson's disease, epilepsy, Alzheimer's disease, and depression is increasing significantly, which is anticipated to propel the demand for neuroprosthetic devices. According to the WHO data published in February 2024, approximately 50 million people worldwide are living with epilepsy. Furthermore, the burden of neurological disorders remains significant across various demographic groups, contributing to the rising demand for neuroprosthetic devices. According to the CDC, approximately 2.9 million U.S. adults aged 18 and older reported having active epilepsy during 2021 and 2022.

Furthermore, the increasing prevalence of physiological disorders, particularly those affecting the auditory, ophthalmic, cardiac, and renal systems, is expected to drive market growth. According to WHO data published in February 2025, around 2.5 billion people may experience some extent of hearing loss by 2050, with over 700 million requiring hearing rehabilitation.

Currently, over 430 million individuals, representing more than 5% of the global population, including 34 million children, require rehabilitation for hearing loss. This number is projected to exceed 700 million, or about 1 in 10 people, by 2050. Around 80% of those with hearing loss live in low- and middle-income countries, and prevalence rises with age, affecting over 25% of adults above 60. This increasing global burden of auditory disorders is expected to drive demand for cochlear implants and support market expansion during the forecast period.

Global Neuroprosthetics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuroprosthetics market report based on type, technology, application, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Motor Prosthetics
• Cochlear Implants
• Cognitive Prosthetics
• Retinal Implants
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Deep Brain Stimulation (DBS)
• Vagus Nerve Stimulation (VNS)
• Spinal Cord Stimulation (SCS)
• Sacral Nerve Stimulation (SNS)
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Motor Neuron Disorders
  • Parkinson's Disease
  • Epilepsy
• Physiological Disorders
  • Auditory Disorders
  • Opthalmic Disorders
  • Cardiac Disorders
  • Kidney Disorders
• Cognitive Disorders
  • Alzheimer's Disease
  • Severe Depression
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Content

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Applications
  • 1.2.3. Technology
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Neuroprosthetics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence of Target Diseases
    • 3.2.1.2. Technological Advancements In Neuroprosthetics
    • 3.2.1.3. Rising Number of Awareness Initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product Recalls
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing Number of Clinical Trials
    • 3.2.3.2. Launches Of Novel Products
    • 3.2.3.3. Increasing Research & Development Activities
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Shortage of Skilled Professionals
    • 3.2.4.2. Potential Complications & Risks Associated with Neuroprosthetics
• 3.3. Neuroprosthetics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Neuroprosthetics Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Type Market Share Analysis, 2024 & 2033
• 4.3. Global Neuroprosthetics Market, by Type, 2021 to 2033
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 4.4.1. Motor Prosthetics
    • 4.4.1.1. Motor prosthetics devices market, 2021 - 2033 (USD Million)
  • 4.4.2. Cochlear Implants
    • 4.4.2.1. Cochlear implants market, 2021 - 2033 (USD Million)
  • 4.4.3. Cognitive Prosthetics
    • 4.4.3.1. Cognitive prosthetics market, 2021 - 2033 (USD Million)
  • 4.4.4. Retinal Implants
    • 4.4.4.1. Retinal implants market, 2021 - 2033 (USD Million)

Chapter 5. Neuroprosthetics Market: Segment Analysis, By Applications, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Applications Market Share Analysis, 2024 & 2033
• 5.3. Global Neuroprosthetics Market, by Applications, 2021 to 2033
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 5.4.1. Motor Neuron Disorders
    • 5.4.1.1. Motor neuron disorders market, 2021 - 2033 (USD Million)
    • 5.4.1.2. Parkinson's Disease
      • 5.4.1.2.1. Parkinson's disease market, 2021 - 2033 (USD Million)
    • 5.4.1.3. Epilepsy
      • 5.4.1.3.1. Epilepsy market, 2021 - 2033 (USD Million)
  • 5.4.2. Physiological Disorders
    • 5.4.2.1. Physiological disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.2. Auditory Disorders
      • 5.4.2.2.1. Auditory disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.3. Ophthalmic Disorders
      • 5.4.2.3.1. Ophthalmic disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.4. Cardiac Disorders
      • 5.4.2.4.1. Cardiac disorders market, 2021 - 2033 (USD Million)
    • 5.4.2.5. Kidney Disorders
      • 5.4.2.5.1. Kidney disorders market, 2021 - 2033 (USD Million)
  • 5.4.3. Cognitive Disorders
    • 5.4.3.1. Cognitive disorders market, 2021 - 2033 (USD Million)
    • 5.4.3.2. Alzheimer's Disease
      • 5.4.3.2.1. Alzheimer's disease market, 2021 - 2033 (USD Million)
    • 5.4.3.3. Severe Depression
      • 5.4.3.3.1. Severe depression market, 2021 - 2033 (USD Million)

Chapter 6. Neuroprosthetics Market: Segment Analysis, By Technology, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. Technology Market Share Analysis, 2024 & 2033
• 6.3. Global Neuroprosthetics Market, by Technology, 2021 to 2033
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 6.4.1. Deep Brain Stimulation
    • 6.4.1.1. Deep brain stimulation market, 2021 - 2033 (USD Million)
  • 6.4.2. Vagus Nerve Stimulation
    • 6.4.2.1. Vagus nerve stimulation market, 2021 - 2033 (USD Million)
  • 6.4.3. Spinal Cord Stimulation
    • 6.4.3.1. Spinal cord stimulation market, 2021 - 2033 (USD Million)
  • 6.4.4. Sacral Nerve Stimulation
    • 6.4.4.1. Sacral nerve stimulation market, 2021 - 2033 (USD Million)

Chapter 7. Neuroprosthetics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Global Key company market share analysis, 2024
  • 8.3.4. Medtronic
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. LivaNova PLC
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Cochlear Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Abbott
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Boston Scientific Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Nevro Corp
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Sonova
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Science Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Advanced Bionics AG
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. MED-EL Medical Electronics
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. ZHEJIANG NUROTRON BIOTECHNOLOGY CO., LTD.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
• 8.4. Heat Map Analysis/ Company Market Position Analysis
• 8.5. Estimated Company Market Share Analysis, 2024
• 8.6. List of Other Key Market Players